Clinical Trial Update: Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-1654-007 evaluating Clesrovimab in infants and children at increased risk for severe respiratory syncytial virus infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Clesrovimab (clesrovimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: RSV Infection | Phase 3 | Status: COMPLETED